<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04328077</url>
  </required_header>
  <id_info>
    <org_study_id>TERN101-2001</org_study_id>
    <nct_id>NCT04328077</nct_id>
  </id_info>
  <brief_title>LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered TERN-101 Tablets in Adult Patients With Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Terns, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Terns, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, double-blind, placebo-controlled study designed to evaluate
      the safety, tolerability, efficacy, and pharmacokinetics (PK) of TERN-101 in non-cirrhotic
      NASH patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject incidence of adverse events for TERN-101 versus placebo</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in ALT for TERN-101 versus placebo at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of TERN-101 - AUC</measure>
    <time_frame>12 weeks</time_frame>
    <description>Area under the curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of TERN-101 - Cmax</measure>
    <time_frame>12 weeks</time_frame>
    <description>Maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of TERN-101 - Tmax</measure>
    <time_frame>12 weeks</time_frame>
    <description>Time to reach maximum measured plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of TERN-101 - t1/2</measure>
    <time_frame>12 weeks</time_frame>
    <description>Determination of half-life</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>TERN-101 dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TERN-101 dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TERN-101 dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Orally administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TERN-101</intervention_name>
    <description>Investigational drug</description>
    <arm_group_label>TERN-101 dose level 1</arm_group_label>
    <arm_group_label>TERN-101 dose level 2</arm_group_label>
    <arm_group_label>TERN-101 dose level 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 to 75 years of age

          -  Overweight or obese with a body mass index (BMI) ≥ 25 kg/m2

          -  Presumed NASH based on clinical characteristics or prior liver biopsy

          -  ALT ≥ 43 IU/L for men and ≥ 28 IU/L for women

          -  MRI PDFF liver fat content ≥ 10 %

          -  Written informed consent

        Exclusion Criteria:

          -  History or clinical evidence of chronic liver diseases other than NAFLD

          -  History or clinical evidence of cirrhosis, hepatic decompensation or other severe
             liver impairment

          -  History of liver transplant, or current placement on a liver transplant list

          -  Total bilirubin &gt; 1.2 mg/dL

          -  Albumin &lt; 3.5 g/dL

          -  INR &gt; 1.1

          -  AST or ALT &gt; 5 x ULN

          -  ALP &gt; 156 IU/L

          -  Platelet count &lt; 150,000 /mm3

          -  eGFR &lt; 60 mL/min/1.73m2

          -  Weight loss &gt; 5% within past 3 months prior to Screening

          -  Uncontrolled diabetes

          -  Uncontrolled hyperlipidemia

          -  Active COVID-19 infection

          -  Other protocol-defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>clinicaltrials@ternspharma.com</last_name>
    <role>Study Director</role>
    <affiliation>Terns, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>650-486-9623</phone>
    <email>clinicaltrials@ternspharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Terns Clinical Study Site 1016</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Terns Clinical Study Site 1008</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Terns Clinical Study Site 1001</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Terns Clinical Study Site 1007</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Terns Clinical Study Site 1010</name>
      <address>
        <city>Bastrop</city>
        <state>Louisiana</state>
        <zip>71220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Terns Clinical Study Site 1005</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Terns Clinical Study Site 1025</name>
      <address>
        <city>Georgetown</city>
        <state>Texas</state>
        <zip>78628</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Terns Clinical Study Site 1006</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Terns Clinical Study Site 1003</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 13, 2020</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Farnesoid X receptor (FXR)</keyword>
  <keyword>NASH</keyword>
  <keyword>Nonalcoholic Steatohepatitis</keyword>
  <keyword>NAFLD</keyword>
  <keyword>Nonalcoholic Fatty Liver Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

